FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q40802018> ?p ?o ?g. }

• Q40802018 description "2016 nî lūn-bûn" @default.
• Q40802018 description "2016年の論文" @default.
• Q40802018 description "2016年学术文章" @default.
• Q40802018 description "2016年学术文章" @default.
• Q40802018 description "2016年学术文章" @default.
• Q40802018 description "2016年学术文章" @default.
• Q40802018 description "2016年学术文章" @default.
• Q40802018 description "2016年學術文章" @default.
• Q40802018 description "2016年學術文章" @default.
• Q40802018 description "2016年學術文章" @default.
• Q40802018 description "2016年學術文章" @default.
• Q40802018 description "2016年學術文章" @default.
• Q40802018 description "2016年學術文章" @default.
• Q40802018 description "2016년 논문" @default.
• Q40802018 description "article científic" @default.
• Q40802018 description "article scientific" @default.
• Q40802018 description "article scientifique (publié 2016)" @default.
• Q40802018 description "articol științific" @default.
• Q40802018 description "articolo scientifico" @default.
• Q40802018 description "artigo científico (publicado na 2016)" @default.
• Q40802018 description "artigo científico (publicado na 2016)" @default.
• Q40802018 description "artigo científico" @default.
• Q40802018 description "artikull shkencor" @default.
• Q40802018 description "artikulong pang-agham" @default.
• Q40802018 description "artykuł naukowy" @default.
• Q40802018 description "artículo científico publicado en 2016" @default.
• Q40802018 description "artículu científicu espublizáu en 2016" @default.
• Q40802018 description "bilimsel makale" @default.
• Q40802018 description "bài báo khoa học" @default.
• Q40802018 description "mokslinis straipsnis" @default.
• Q40802018 description "naučni članak" @default.
• Q40802018 description "scienca artikolo" @default.
• Q40802018 description "scientific article" @default.
• Q40802018 description "teaduslik artikkel" @default.
• Q40802018 description "tieteellinen artikkeli" @default.
• Q40802018 description "tudományos cikk" @default.
• Q40802018 description "vedecký článok" @default.
• Q40802018 description "vetenskaplig artikel" @default.
• Q40802018 description "videnskabelig artikel (udgivet 2016)" @default.
• Q40802018 description "vitenskapelig artikkel" @default.
• Q40802018 description "vitskapeleg artikkel" @default.
• Q40802018 description "vědecký článek" @default.
• Q40802018 description "wetenschappelijk artikel" @default.
• Q40802018 description "wissenschaftlicher Artikel" @default.
• Q40802018 description "επιστημονικό άρθρο" @default.
• Q40802018 description "мақолаи илмӣ" @default.
• Q40802018 description "мақолаи илмӣ" @default.
• Q40802018 description "наукова стаття, опублікована в лютому 2016" @default.
• Q40802018 description "научна статия" @default.
• Q40802018 description "научная статья" @default.
• Q40802018 description "научни чланак" @default.
• Q40802018 description "научни чланак" @default.
• Q40802018 description "գիտական հոդված" @default.
• Q40802018 description "מאמר מדעי" @default.
• Q40802018 description "سائنسی مضمون" @default.
• Q40802018 description "مقالة علمية نشرت بتاريخ 4-2-2016" @default.
• Q40802018 description "مقالهٔ علمی" @default.
• Q40802018 description "২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q40802018 description "บทความทางวิทยาศาสตร์" @default.
• Q40802018 description "სამეცნიერო სტატია" @default.
• Q40802018 name "A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients" @default.
• Q40802018 type Item @default.
• Q40802018 label "A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients" @default.
• Q40802018 prefLabel "A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients" @default.
• Q40802018 P1433 Q40802018-2527E6C6-BFDC-45FF-9BDB-293958E98074 @default.
• Q40802018 P1476 Q40802018-47C1474A-F32A-48F8-97C6-472087C7CFEF @default.
• Q40802018 P2093 Q40802018-108B6FEC-6B96-4144-8F01-DD8EAA49A5A6 @default.
• Q40802018 P2093 Q40802018-3CDA9B06-31E8-4D9C-8E00-3FB1323E4420 @default.
• Q40802018 P2093 Q40802018-9EFBF4D7-5D7B-4DA9-8C8F-7DD7FCBEF0A0 @default.
• Q40802018 P2093 Q40802018-A7BFB660-8392-4D05-8A96-427BD4AF9F1C @default.
• Q40802018 P304 Q40802018-99CAC1B7-6A09-4E06-8990-823CB2F38C44 @default.
• Q40802018 P31 Q40802018-4F9DC550-7ADF-42A8-9683-544CFEA2E775 @default.
• Q40802018 P356 Q40802018-660B388D-075E-4680-BCD1-CC39B4A6512C @default.
• Q40802018 P433 Q40802018-CFD0F782-B2A6-409C-BB5F-E79AED53937F @default.
• Q40802018 P478 Q40802018-E53886D7-AD43-4217-9C20-C7A5AB96D6A5 @default.
• Q40802018 P50 Q40802018-1CEA7C72-3A30-431D-9705-2E0917B0A72F @default.
• Q40802018 P50 Q40802018-3BDFF6D3-2361-4E94-A375-8F54DA096E75 @default.
• Q40802018 P50 Q40802018-AE86FC5D-1F38-4A55-94C3-F3FF642F22A4 @default.
• Q40802018 P50 Q40802018-B508C1B8-4C23-4123-B640-61E8880BC460 @default.
• Q40802018 P50 Q40802018-C97C5427-BB43-4FF8-9968-3DAD24E32B77 @default.
• Q40802018 P50 Q40802018-E7E0C58B-28A3-49E3-BFFF-B983800BCC8B @default.
• Q40802018 P50 Q40802018-EB8F0DA4-A8D3-4340-8CB9-63F3BE212695 @default.
• Q40802018 P50 Q40802018-F04E611A-F8B1-4973-9DA7-7ADDB3219B2B @default.
• Q40802018 P50 Q40802018-FCAE2BE5-7DF9-4422-AFB5-DDF70A368BA7 @default.
• Q40802018 P577 Q40802018-00021045-92E2-4C00-8858-1E56E5DA2FB6 @default.
• Q40802018 P698 Q40802018-6A5E312C-4D3B-41E4-93CC-73807885451C @default.
• Q40802018 P921 Q40802018-670A96A7-4EE4-4231-95DD-237DFDCD87AC @default.
• Q40802018 P921 Q40802018-7E20AD8F-AB18-411F-BF2B-D8A26D3E82D0 @default.
• Q40802018 P921 Q40802018-F69C0F80-6436-469B-8BFE-1097128A0718 @default.
• Q40802018 P356 J.JCF.2015.12.004 @default.
• Q40802018 P698 26852040 @default.
• Q40802018 P1433 Q15749341 @default.
• Q40802018 P1476 "A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients" @default.
• Q40802018 P2093 "David E Geller" @default.
• Q40802018 P2093 "Elizabeth E Morgan" @default.
• Q40802018 P2093 "Jeffery S Loutit" @default.
• Q40802018 P2093 "Rainald Fischer" @default.
• Q40802018 P304 "495-502" @default.
• Q40802018 P31 Q13442814 @default.
• Q40802018 P356 "10.1016/J.JCF.2015.12.004" @default.

• next